Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

bioAffinity Technologies (BIAF) Revenue: 2022-2025

Historic Revenue for bioAffinity Technologies (BIAF) over the last 4 years, with Sep 2025 value amounting to $1.4 million.

  • bioAffinity Technologies' Revenue fell 38.48% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.8 million, marking a year-over-year decrease of 27.66%. This contributed to the annual value of $9.4 million for FY2024, which is 269.68% up from last year.
  • Latest data reveals that bioAffinity Technologies reported Revenue of $1.4 million as of Q3 2025, which was up 13.91% from $1.3 million recorded in Q2 2025.
  • In the past 5 years, bioAffinity Technologies' Revenue ranged from a high of $2.4 million in Q1 2024 and a low of -$1.1 million during Q2 2022.
  • For the 3-year period, bioAffinity Technologies' Revenue averaged around $1.5 million, with its median value being $1.9 million (2025).
  • Per our database at Business Quant, bioAffinity Technologies' Revenue soared by 261,180.24% in 2024 and then tumbled by 47.05% in 2025.
  • Quarterly analysis of 4 years shows bioAffinity Technologies' Revenue stood at $2,346 in 2022, then soared by 94,245.95% to $2.2 million in 2023, then dropped by 0.26% to $2.2 million in 2024, then slumped by 38.48% to $1.4 million in 2025.
  • Its Revenue stands at $1.4 million for Q3 2025, versus $1.3 million for Q2 2025 and $1.9 million for Q1 2025.